Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Agendia To Determine Scope Of MammaPrint Premarket Regulation

This article was originally published in The Gray Sheet

Executive Summary

Agendia's MammaPrint breast cancer recurrence assay may qualify for a CLIA waiver and require no further premarket regulation, the company says

You may also be interested in...



Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits

Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market

Exagen Files First Of Six Planned 510(k)s For Genomic Test Kits

Exagen Diagnostics recently filed the first of six planned 510(k) applications for test kits developed using its novel Coperna computational platform, kicking off a major push into the nascent genomic test kit market

Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule

FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing

Related Content

UsernamePublicRestriction

Register

MT022105

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel